Avenzo Therapeutics and Dualitybio Announce Exclusive Global License for Potential Best-in-Class Egfr/Her3 Antibody-Drug Conjugate
Avenzo Therapeutics和Dualitybio宣佈獲得潛在最佳抗EGFR/Her3抗體藥物綴合物的全球獨家許可
Avenzo Therapeutics and Dualitybio Announce Exclusive Global License for Potential Best-in-Class Egfr/Her3 Antibody-Drug Conjugate
Avenzo Therapeutics和Dualitybio宣佈獲得潛在最佳抗EGFR/Her3抗體藥物綴合物的全球獨家許可
使用瀏覽器的分享功能,分享給你的好友吧